Radiation plus immunotherapy and targeted therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether combining radiation therapy with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—can shrink liver cancer that has spread into the main portal vein. It’s for people with advanced liver cancer who haven’t had any systemic treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced liver cancer (called hepatocellular carcinoma) that has spread to the main portal vein (the large blood vessel supplying your liver).
- You have not had any previous systemic treatment (medication that works throughout your body) for your liver cancer.
- Up to 10 tumors in your liver or other parts of your body, and any tumor outside your liver is no larger than 5 cm.
- Your liver function is good (Child-Pugh score A or B, with a score of 7 or less).
- You have not had a PD-1 inhibitor (like Keytruda or Opdivo) or the drug apatinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main vein of the liver. It is for patients who have not had any prior treatment for their liver cancer.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.